Importantly, single-agent anti-PD-1 has demonstrated activity in isolated cases with GBM associated with germline mismatch repair deficiency30,31 and in newly diagnosed patients with MGMT methylated GBM treated in the neoadjuvant setting12. This evidence concerns the gene PDCD1 and glioblastoma.